Drug intelligence / Profile preview

BAY1753011 + furosemide

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

BAY1753011 + furosemide is a combination of a novel, dual-acting vasopressin receptor antagonist (BAY1753011) and the loop diuretic furosemide. **BAY1753011** targets both V1a and V2 vasopressin receptors, blocking vasopressin-induced water retention and vasoconstriction, as well as exerting antifibrotic and antihypertrophic effects. **Furosemide** is a potent loop diuretic, commonly used for the treatment of hypertension and edema associated with conditions such as congestive heart failure, cirrhosis, and renal disease, acting through inhibition of sodium-potassium-chloride cotransport in the nephron. The combination aims for **decongestion and vascular protection in heart failure** while limiting the activation of the renin-angiotensin system, exploiting both diuretic and vasopressin antagonism mechanisms[1][2][3].

Brand names
Lasix
Other names
furosemide
02

Targets

NKCC2 (Sodium-potassium-chloride cotransporter 2)AVPR1A (Arginine vasopressin receptor 1A)Oxytocin receptorADRA1B (α1B)

Beyond the preview

Go deeper on BAY1753011 + furosemide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY1753011 + furosemide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call